RedHill Biopharma to Present at German Equity Forum 2020
November 13 2020 - 7:00AM
RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”),
a specialty biopharmaceutical company, today announced that Mr. Guy
Goldberg, RedHill’s Chief Business Officer, will present a
corporate overview and host 1-on-1 investor meetings at the German
Equity Forum (Deutsches Eigenkapital Forum) 2020, one of Europe’s
largest investor events, on
Tuesday, November 17, 2020, at
9:30 a.m. CET.
The presentation will be available via replay
for 30 days on the Company's website:
https://ir.redhillbio.com.
About RedHill
Biopharma
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty
biopharmaceutical company primarily focused on gastrointestinal and
infectious diseases. RedHill promotes the gastrointestinal drugs
Movantik® for opioid-induced
constipation in adults1, Talicia®
for the treatment of Helicobacter pylori (H. pylori) infection in
adults2, and Aemcolo® for the
treatment of travelers’ diarrhea in adults3. RedHill’s key clinical
late-stage development programs include: (i)
RHB-204, with a planned Phase 3 study for
pulmonary nontuberculous mycobacteria (NTM) infections; (ii)
opaganib
(Yeliva®), a
first-in-class SK2 selective
inhibitor targeting multiple indications with a Phase 2/3 program
for COVID-19 and Phase 2 studies for prostate cancer and
cholangiocarcinoma ongoing; (iii) RHB-104, with
positive results from a first Phase 3 study for Crohn's disease;
(iv) RHB-102
(Bekinda®), with positive results
from a Phase 3 study for acute gastroenteritis and gastritis and
positive results from a Phase 2 study for IBS-D; (v)
RHB-107, a Phase 2-stage first-in-class, serine
protease inhibitor, targeting cancer and inflammatory
gastrointestinal diseases and is also being evaluated for COVID-19
and (vi) RHB-106, an encapsulated
bowel preparation. More information about the Company is available
at www.redhillbio.com.
This press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements may be preceded by the words
“intends,” “may,” “will,” “plans,” “expects,” “anticipates,”
“projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,”
“potential” or similar words. Forward-looking statements are based
on certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control and cannot be predicted or quantified, and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include risks and uncertainties associated with (i)
the initiation, timing, progress and results of the Company’s
research, manufacturing, preclinical studies, clinical trials, and
other therapeutic candidate development efforts, and the timing of
the commercial launch of its commercial products and ones it may
acquire or develop in the future; (ii) the Company’s ability to
advance its therapeutic candidates into clinical trials or to
successfully complete its preclinical studies or clinical trials
(iii) the extent and number and type of additional studies that the
Company may be required to conduct and the Company’s receipt of
regulatory approvals for its therapeutic candidates, and the timing
of other regulatory filings, approvals and feedback; (iv) the
manufacturing, clinical development, commercialization, and market
acceptance of the Company’s therapeutic candidates and Talicia®;
(v) the Company’s ability to successfully commercialize and promote
Movantik®, Talicia® and Aemcolo®; (vi) the Company’s ability to
establish and maintain corporate collaborations; (vii) the
Company's ability to acquire products approved for marketing in the
U.S. that achieve commercial success and build and sustain its own
marketing and commercialization capabilities; (viii) the
interpretation of the properties and characteristics of the
Company’s therapeutic candidates and the results obtained with its
therapeutic candidates in research, preclinical studies or clinical
trials; (ix) the implementation of the Company’s business model,
strategic plans for its business and therapeutic candidates; (x)
the scope of protection the Company is able to establish and
maintain for intellectual property rights covering its therapeutic
candidates and commercial products and its ability to operate its
business without infringing the intellectual property rights of
others; (xi) parties from whom the Company licenses its
intellectual property defaulting in their obligations to the
Company; (xii) estimates of the Company’s expenses, future
revenues, capital requirements and needs for additional financing;
(xiii) the effect of patients suffering adverse events using
investigative drugs under the Company's Expanded Access Program;
and (xiv) competition from other companies and technologies within
the Company’s industry. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company's filings
with the Securities and Exchange Commission (SEC), including the
Company's Annual Report on Form 20-F filed with the SEC on March 4,
2020. All forward-looking statements included in this press release
are made only as of the date of this press release. The Company
assumes no obligation to update any written or oral forward-looking
statement, whether as a result of new information, future events or
otherwise unless required by law.
Company contact:Adi FrishChief Corporate &
Business Development Officer RedHill
Biopharma+972-54-6543-112adi@redhillbio.com |
Media contact (U.S.):Bryan
GibbVice PresidentFinn Partners+1 212 529
2236bryan.gibbs@finnpartners.com |
_____________1 Full prescribing information for
Movantik® (naloxegol) is available at: www.Movantik.com. 2 Full
prescribing information for Talicia® (omeprazole magnesium,
amoxicillin and rifabutin) is available at: www.Talicia.com.
3 Full prescribing information
for Aemcolo® (rifamycin) is available at: www.Aemcolo.com.
Redhill Biopharma (NASDAQ:RDHL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Redhill Biopharma (NASDAQ:RDHL)
Historical Stock Chart
From Sep 2023 to Sep 2024